GLP1R and Schnyder corneal dystrophy: There was no difference in risk of hypoglycemia (HR 1.10, 95% CI 0.60-1.76; P = 0.688) or progression to CKD between the two groups (HR 1.26, 95% CI 0.82-1.95; P = 0.294).<h4>Conclusions</h4>GLP-1 therapies demonstrate favorable cardioprotective, vaso stabilizing, and safety benefits in adults with SCD and T2DM, supporting their use in this high-risk population.<h4>Clinical trial number</h4>Not applicable.